• Profile
Close

Clinical effectiveness of antifibrotic medications for idiopathic pulmonary fibrosis

American Journal of Respiratory and Critical Care Medicine Jul 18, 2019

Dempsey TM, et al. - Researchers used an extensive U.S. insurance database, to assess the clinical efficacy of pirfenidone and nintedanib (antifibrotic medications) in patients with idiopathic pulmonary fibrosis (n=8,098). For comparing patients who received antifibrotic medications (n = 1,255) to those not on treatment (n = 1,255), they created a one-to-one propensity score–matched cohort. Patients taking pirfenidone did not differ significantly from those on nintedanib with regard to all-cause mortality. Based on the findings, they concluded that lower risk of all-cause mortality and hospitalization may be seen in patients with idiopathic pulmonary fibrosis in relation to treatment with antifibrotic agents vs no treatment. As shown in this study, early but not long-term mortality was reduced by these treatments.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay